Prurigo Nodularis

• EMA approval · 2026-04-20
  EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

  The EMA authorised Dupixent (dupilumab) for multiple EU indications, including atopic dermatitis, prurigo nodularis, eosinophilic esophagiti…

• FDA approval · 2024-09-12
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for Dupixent (dupilumab) submitted by sanofi-aventis U.S. LLC.